JP6483714B2 - 噴霧乾燥製剤 - Google Patents

噴霧乾燥製剤 Download PDF

Info

Publication number
JP6483714B2
JP6483714B2 JP2016547977A JP2016547977A JP6483714B2 JP 6483714 B2 JP6483714 B2 JP 6483714B2 JP 2016547977 A JP2016547977 A JP 2016547977A JP 2016547977 A JP2016547977 A JP 2016547977A JP 6483714 B2 JP6483714 B2 JP 6483714B2
Authority
JP
Japan
Prior art keywords
substituted
groups
unsubstituted
group
formulation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2016547977A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016534153A5 (enExample
JP2016534153A (ja
Inventor
ローレンス エス． ジスマン，
ローレンス エス． ジスマン，
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of JP2016534153A publication Critical patent/JP2016534153A/ja
Publication of JP2016534153A5 publication Critical patent/JP2016534153A5/ja
Application granted granted Critical
Publication of JP6483714B2 publication Critical patent/JP6483714B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2016547977A 2013-10-11 2014-10-10 噴霧乾燥製剤 Active JP6483714B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361889887P 2013-10-11 2013-10-11
US61/889,887 2013-10-11
PCT/US2014/060039 WO2015054574A1 (en) 2013-10-11 2014-10-10 Spray dry formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019024568A Division JP6823095B2 (ja) 2013-10-11 2019-02-14 噴霧乾燥製剤

Publications (3)

Publication Number Publication Date
JP2016534153A JP2016534153A (ja) 2016-11-04
JP2016534153A5 JP2016534153A5 (enExample) 2017-11-16
JP6483714B2 true JP6483714B2 (ja) 2019-03-13

Family

ID=52813663

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2016547977A Active JP6483714B2 (ja) 2013-10-11 2014-10-10 噴霧乾燥製剤
JP2019024568A Active JP6823095B2 (ja) 2013-10-11 2019-02-14 噴霧乾燥製剤
JP2021001507A Pending JP2021063119A (ja) 2013-10-11 2021-01-07 噴霧乾燥製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2019024568A Active JP6823095B2 (ja) 2013-10-11 2019-02-14 噴霧乾燥製剤
JP2021001507A Pending JP2021063119A (ja) 2013-10-11 2021-01-07 噴霧乾燥製剤

Country Status (8)

Country Link
US (2) US9925184B2 (enExample)
EP (1) EP3054937B1 (enExample)
JP (3) JP6483714B2 (enExample)
CN (2) CN111743901B (enExample)
AU (3) AU2014331796B2 (enExample)
CA (1) CA2926793C (enExample)
ES (1) ES2959419T3 (enExample)
WO (1) WO2015054574A1 (enExample)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9757395B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
US9757529B2 (en) 2012-12-20 2017-09-12 Otitopic Inc. Dry powder inhaler and methods of use
EP3007689B1 (en) 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
CA2910766C (en) 2013-04-30 2020-12-15 Otitopic Inc. Dry powder formulations and methods of use
PL3060041T3 (pl) 2013-10-25 2021-08-02 Insmed Incorporated Związki prostacykliny
ES2873873T3 (es) 2014-11-18 2021-11-04 Insmed Inc Métodos de fabricación de treprostinilo y profármacos derivados de treprostinilo
JP2019504684A (ja) * 2016-01-29 2019-02-21 マンカインド コーポレイション 乾燥粉末吸入器
IL319790A (en) * 2016-05-05 2025-05-01 Liquidia Tech Inc Terpostinil in dry powder form for the treatment of pulmonary hypertension
GB201609940D0 (en) * 2016-06-07 2016-07-20 Novabiotics Ltd Microparticles
US20170360840A1 (en) * 2016-06-17 2017-12-21 United Therapeutics Corporation Extracellular vesicles with enhanced potency
KR20230093341A (ko) * 2016-10-27 2023-06-27 풀모킨 인코포레이티드 폐고혈압을 치료하기 위한 병용 요법
US10786456B2 (en) 2017-09-22 2020-09-29 Otitopic Inc. Inhaled aspirin and magnesium to treat inflammation
CA3076353A1 (en) 2017-09-22 2019-03-28 Otitopic Inc. Dry powder compositions with magnesium stearate
WO2019157337A1 (en) * 2018-02-08 2019-08-15 Pulmokine, Inc. Formulations of kinase inhibitors and prostanoids
US20210386665A1 (en) * 2018-10-02 2021-12-16 Meijo University Educational Foundation Inhalation powder medicine, evaluation method thereof, and use thereof
JP7455144B2 (ja) 2019-04-29 2024-03-25 インスメッド インコーポレイテッド トレプロスチニルプロドラッグの乾燥粉末組成物およびその使用方法
US11464776B2 (en) 2019-05-16 2022-10-11 Aerovate Therapeutics, Inc. Inhalable imatinib formulations, manufacture, and uses thereof
US20200360277A1 (en) 2019-05-16 2020-11-19 Aerovate Therapeutics, Inc. Inhalable formulations of imatinib, imatinib metabolites, imatinib salts, their manufacture, and uses thereof
WO2021201258A1 (ja) * 2020-04-01 2021-10-07 株式会社ＳｔａｔｅＡｒｔ 核酸含有組成物、核酸含有組成物の製造方法及び核酸導入方法
WO2022109458A1 (en) * 2020-11-23 2022-05-27 Aerovate Therapeutics, Inc. Imatinib formulations, manufacture, and uses thereof
AU2022270171B2 (en) 2021-05-07 2026-01-08 Gb002, Inc. Crystalline forms of n-{3-[(1s)-1-{[6-(3,4-dimethoxyphenyl)pyrazin-2-yl]amino}ethyl]phenyl}-5-methylpyridine-3-carboxamide and related products and methods
WO2024035884A1 (en) 2022-08-10 2024-02-15 Gb002, Inc. Tyrosine kinase inhibitor and activin type 2 receptor antagonist combination therapy for treating pulmonary arterial hypertension (pah)

Family Cites Families (62)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4118401A (en) 1977-10-19 1978-10-03 American Hoechst Corporation Preparation of 6,11-dihydro-11-oxodibenz[b,e]oxepin-2-acetic acid and precursors therefor
JPS5488231A (en) 1977-12-22 1979-07-13 Sumitomo Chem Co Ltd 3-phenyloxymethylaniline derivative, its preparation, and herbicides consisting of it
US4570630A (en) 1983-08-03 1986-02-18 Miles Laboratories, Inc. Medicament inhalation device
DE3632329A1 (de) 1986-09-24 1988-03-31 Bayer Ag Substituierte phenylsulfonamide
US5648369A (en) 1991-11-20 1997-07-15 University Of Kentucky Research Foundation Aminoalkylpyridine compounds which are useful as anitconvulsant drugs, excitatory amino acid inhibitors and NMDA sigma receptor antagonists
PL325277A1 (en) 1995-08-30 1998-07-20 Bayer Ag Acylamino salicylamide compounds
JPH09268169A (ja) 1996-04-01 1997-10-14 Otsuka Chem Co Ltd サリチル酸アニリド誘導体、それを有効成分として含む植物病害防除剤
DE69837903T2 (de) 1997-08-11 2008-02-14 Pfizer Products Inc., Groton Feste pharmazeutische Dispersionen mit erhöhter Bioverfügbarkeit
US6015815A (en) * 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
CA2382821A1 (en) * 1999-08-25 2001-03-01 Advanced Inhalation Research, Inc. Modulation of release from dry powder formulations
US6458849B1 (en) 1999-09-23 2002-10-01 G.D. Searle & Co. use of substituted N,N-disubstituted mercapto amino compounds for inhibiting cholesteryl ester transfer protein activity
WO2001028993A2 (en) 1999-10-19 2001-04-26 Merck & Co. Inc. Tyrosine kinase inhibitors
DZ3223A1 (fr) 1999-10-19 2001-04-26 Merck & Co Inc Inhibiteurs de tyrosine kinases
HN2001000008A (es) 2000-01-21 2003-12-11 Inc Agouron Pharmaceuticals Compuesto de amida y composiciones farmaceuticas para inhibir proteinquinasas, y su modo de empleo
JP2003523390A (ja) 2000-02-25 2003-08-05 メルク エンド カムパニー インコーポレーテッド チロシンキナーゼ阻害薬
US6420382B2 (en) 2000-02-25 2002-07-16 Merck & Co., Inc. Tyrosine kinase inhibitors
JP2004528295A (ja) 2001-01-30 2004-09-16 サイトピア ピーティワイ リミテッド キナーゼ阻害方法
US6825198B2 (en) 2001-06-21 2004-11-30 Pfizer Inc 5-HT receptor ligands and uses thereof
NZ537155A (en) 2002-05-23 2006-09-29 Cytopia Pty Ltd Protein kinase inhibitors
EP1532067B1 (en) 2002-05-23 2008-09-17 Cohen, Ben Z. Medically accurate pump system
AUPS251502A0 (en) * 2002-05-23 2002-06-13 Cytopia Pty Ltd Protein kinase inhibitors
WO2003099811A1 (en) 2002-05-23 2003-12-04 Cytopia Pty Ltd Kinase inhibitors
EP2508204B1 (en) 2002-06-26 2014-09-24 Ono Pharmaceutical Co., Ltd. Remedies for diseases caused by vascular contraction or dilation
JP2005538975A (ja) 2002-07-03 2005-12-22 アステックス テクノロジー リミテッド ｐ３８ＭＡＰキナーゼ阻害薬としての３−（ヘテロ）アリールメトキシピリジン類およびそれらの類縁体
CA2492593A1 (en) 2002-07-15 2004-01-22 Myriad Genetics, Inc. Compounds, compositions, and methods employing same
JP4942297B2 (ja) 2002-10-25 2012-05-30 ジ アドミニストレイターズ オブ ザ チューレン エデュケイショナル ファンド 肺高血圧症の処置を目的としたｎ−｛５−［４−（４−メチルピペラジノメチル）−ベンゾイルアミド］−２−メチルフェニル｝−４−（３−ピリジル）−２−ピリジン−アミンの使用
AU2002953255A0 (en) 2002-12-11 2003-01-02 Cytopia Research Pty Ltd Protein kinase inhibitors
WO2005002673A1 (en) 2003-07-03 2005-01-13 Astex Therapeutics Limited Raf kinase inhibitors
US20050026879A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a tyrosine kinase inhibitor, delta opioid receptor antagonist, neurokinin receptor antagonist, or VCAM inhibitor for treatment of asthma or chronic obstructive pulmonary disease
FR2858459B1 (fr) 2003-08-01 2006-03-10 Commissariat Energie Atomique Commutateur micro-mecanique bistable, methode d'actionnement et procede de realisation correspondant
EP1663211B1 (en) 2003-08-06 2010-01-20 Vertex Pharmaceuticals Incorporated Aminotriazole compounds useful as inhibitors of protein kinases
WO2005047244A2 (en) 2003-11-07 2005-05-26 Chiron Corporation Inhibition of fgfr3 and treatment of multiple myeloma
CA2545425C (en) 2003-12-03 2013-09-24 Cytopia Research Pty Ltd Azole-based kinase inhibitors
AU2004294354B2 (en) 2003-12-03 2009-02-19 Ym Biosciences Australia Pty Ltd Tubulin inhibitors
DK1704145T3 (da) 2004-01-12 2012-09-24 Ym Biosciences Australia Pty Selektive kinaseinhibitorer
US20080268460A1 (en) 2004-05-20 2008-10-30 Wyeth Assays to Identify Irreversibly Binding Inhibitors of Receptor Tyrosine Kinases
JP2006111553A (ja) 2004-10-13 2006-04-27 Dainippon Sumitomo Pharma Co Ltd スルホニルオキシインドール誘導体及びそれを含有する医薬組成物
EP1948176B1 (en) 2005-11-10 2011-01-05 Bayer Schering Pharma Aktiengesellschaft Diaryl ureas for treating pulmonary hypertension
US20090197922A1 (en) 2006-01-24 2009-08-06 The University Of Chicago Compositions and methods for treating pulmonary hypertension
AU2007220047B2 (en) 2006-02-28 2013-08-01 Ym Biosciences Australia Pty Ltd Inhibition of JAK2 as a treatment of pulmonary arterial hypertension
WO2007124382A2 (en) 2006-04-19 2007-11-01 Novartis Vaccines And Diagnostics, Inc. Inhaled imipenem
EP2099774A4 (en) * 2006-11-15 2010-11-24 Ym Biosciences Australia Pty L INHIBITORS OF KINASEACTIVITY
EA019524B1 (ru) 2007-05-04 2014-04-30 Айрм Ллк СОЕДИНЕНИЯ И КОМПОЗИЦИИ КАК ИНГИБИТОРЫ КИНАЗЫ с-kit И PDGFR
ATE544761T1 (de) 2007-05-04 2012-02-15 Irm Llc Pyrimidinderivate und zusammensetzungen als c-kit-und pdgfr-kinasehemmer
JP5303557B2 (ja) 2007-08-22 2013-10-02 アイアールエム・リミテッド・ライアビリティ・カンパニー キナーゼ阻害剤である２−ヘテロアリールアミノ−ピリミジン誘導体
AU2008289037B2 (en) 2007-08-22 2012-03-01 Novartis Ag 5- (4- (haloalkoxy) phenyl) pyrimidine-2-amine compounds and compositions as kinase inhibitors
SG186679A1 (en) 2007-12-20 2013-01-30 Bayer Schering Pharma Ag 4-(4-cyano-2-thioaryl)dihydropyrimidinones and use thereof
RU2011109078A (ru) 2008-08-13 2012-09-20 Новартис АГ (CH) Лечение легочной артериальной гипертензии
DE102009004197A1 (de) 2009-01-09 2010-07-15 Bayer Schering Pharma Aktiengesellschaft Heterocyclisch anellierte Diaryldihydropyrimidin-Derivate und ihre Verwendung
US8685458B2 (en) 2009-03-05 2014-04-01 Bend Research, Inc. Pharmaceutical compositions of dextran polymer derivatives
WO2010132827A1 (en) 2009-05-15 2010-11-18 Bend Research, Inc. Low-molecular dextran for powder inhalations
TWI598347B (zh) 2009-07-13 2017-09-11 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
EP2611529B1 (en) 2010-09-03 2019-01-23 Bend Research, Inc. Spray-drying method
US9248584B2 (en) 2010-09-24 2016-02-02 Bend Research, Inc. High-temperature spray drying process and apparatus
JOP20120023B1 (ar) * 2011-02-04 2022-03-14 Novartis Ag صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
CA2981038C (en) 2011-05-19 2018-09-25 Savara Inc. Dry powder vancomycin compositions and associated methods
JP6134319B2 (ja) 2011-09-01 2017-05-24 ノバルティス アーゲー ｃ−ｋｉｔキナーゼインヒビターとしての化合物及び組成物
US9199981B2 (en) 2011-09-01 2015-12-01 Novartis Ag Compounds and compositions as C-kit kinase inhibitors
EP3007689B1 (en) * 2013-01-10 2018-03-07 Pulmokine, Inc. Non-selective kinase inhibitors
WO2014110198A2 (en) 2013-01-10 2014-07-17 Zisman Lawrence S Therapeutic indications of kinase inhibitors
CA2919498C (en) 2013-07-31 2023-07-25 Windward Pharma, Inc. Aerosol nintedanib compounds and uses thereof
WO2015179369A1 (en) 2014-05-20 2015-11-26 Infinity Pharmaceuticals, Inc. Treatment of pulmonary or respiratory diseases by inhalation administration of pi3 kinase inhibitors

Also Published As

Publication number Publication date
US20180193336A1 (en) 2018-07-12
EP3054937A4 (en) 2017-05-03
EP3054937A1 (en) 2016-08-17
US20160235742A1 (en) 2016-08-18
CN111743901A (zh) 2020-10-09
CA2926793C (en) 2022-11-22
JP6823095B2 (ja) 2021-01-27
JP2021063119A (ja) 2021-04-22
AU2020202556A1 (en) 2020-05-07
WO2015054574A1 (en) 2015-04-16
AU2022203611A1 (en) 2022-06-16
AU2014331796A1 (en) 2016-04-28
CN106132403B (zh) 2020-04-28
JP2016534153A (ja) 2016-11-04
US9925184B2 (en) 2018-03-27
CN111743901B (zh) 2023-09-12
EP3054937B1 (en) 2023-07-26
ES2959419T3 (es) 2024-02-26
AU2014331796B2 (en) 2020-05-07
CA2926793A1 (en) 2015-04-16
JP2019089830A (ja) 2019-06-13
CN106132403A (zh) 2016-11-16

Similar Documents

Publication Publication Date Title
JP6823095B2 (ja) 噴霧乾燥製剤
AU2023201605B2 (en) Non-selective kinase inhibitors
JP2016506417A (ja) キナーゼ阻害剤の治療指標
HK40036372B (zh) 喷雾干燥制剂
HK40036372A (en) Spray dry formulations

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20160920

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20160921

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20160920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171005

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20171005

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180612

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20180613

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180907

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180927

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20181102

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181220

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190116

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190214

R150 Certificate of patent or registration of utility model

Ref document number: 6483714

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R360 Written notification for declining of transfer of rights

Free format text: JAPANESE INTERMEDIATE CODE: R360

R371 Transfer withdrawn

Free format text: JAPANESE INTERMEDIATE CODE: R371

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313114

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250